Feed TBPH
TB

Theravance Biopharma Inc TBPH · NASDAQ

$17.03 -0.12% (-$0.02)

Summary

64 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 52 USD is left as net profit.
  • Revenue grew by 28% a year over the last 3 years.
  • It holds more cash than debt: $219.8M against $38.6M.
  • The share price is below the Bulios Fair Price.

What to watch

  • It earns only 0.9 USD a year on every 100 USD of invested capital.
  • It missed profit estimates 4 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap

Price against the Bulios Fair Price

P/E against the industry (Biotechnology)

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 16.4 USD for 1 USD of yearly profit.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 8.4% a year over 5 years. Over the last 3 years it grew by 28% a year.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Biotechnology) 27 USD

Out of every 100 USD of revenue, 52 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $17 is at today's price. 24% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Collaborative Arrangement Revenue brings in 70% of revenue.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.